Ubs Oconnor LLC Oric Pharmaceuticals, Inc. Call Options Transaction History
Ubs Oconnor LLC
- $1.59 Billion
- Q1 2024
Call Options
1 transactions
Others Institutions Holding ORIC
# of Institutions
112Shares Held
59.3MCall Options Held
302KPut Options Held
7.7K-
Nextech Invest Ag5.29MShares$53.2 Million13.59% of portfolio
-
Vr Adviser, LLC New York, NY4.39MShares$44.2 Million5.19% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA4.14MShares$41.7 Million2.99% of portfolio
-
Viking Global Investors LP4MShares$40.2 Million0.21% of portfolio
-
Alkeon Capital Management LLC New York, NY3.7MShares$37.3 Million0.09% of portfolio
About Oric Pharmaceuticals, Inc.
- Ticker ORIC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,576,700
- Market Cap $398M
- Description
- ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...